{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=93",
    "query": {
      "condition": "Refractory Malignancy",
      "page": 93
    },
    "page_size": 10
  },
  "pagination": {
    "page": 93,
    "page_size": 10,
    "total_count": 5769,
    "total_pages": 577,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=94&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=92&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T11:51:58.677Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00993044",
      "title": "A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Solid Tumors in Children"
      ],
      "interventions": [
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "12 Months to 20 Years"
      },
      "enrollment_count": 13,
      "start_date": "2009-09",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2023-10-06",
      "last_synced_at": "2026-11-19T11:51:58.677Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00993044"
    },
    {
      "nct_id": "NCT01707004",
      "title": "Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome",
        "Adult Acute Myeloid Leukemia in Remission",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Del(5q)",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "de Novo Myelodysplastic Syndromes",
        "Previously Treated Myelodysplastic Syndromes",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "decitabine",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2013-05-16",
      "completion_date": "2017-10-07",
      "has_results": true,
      "last_update_posted_date": "2019-11-21",
      "last_synced_at": "2026-11-19T11:51:58.677Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01707004"
    },
    {
      "nct_id": "NCT00044304",
      "title": "Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Eosinophilic Myeloid Neoplasm",
        "Hypereosinophilic Syndrome"
      ],
      "interventions": [
        {
          "name": "Imatinib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2002-09-26",
      "completion_date": "2027-03-10",
      "has_results": true,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-19T11:51:58.677Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00044304"
    },
    {
      "nct_id": "NCT02109224",
      "title": "Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult B Acute Lymphoblastic Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Cutaneous B-Cell Non-Hodgkin Lymphoma",
        "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "HIV Infection",
        "Intraocular Lymphoma",
        "Multicentric Angiofollicular Lymphoid Hyperplasia",
        "Nodal Marginal Zone Lymphoma",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Immunoblastic Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Hairy Cell Leukemia",
        "Refractory Plasma Cell Myeloma",
        "Small Intestinal Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Testicular Lymphoma",
        "Waldenstrom Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2014-09",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-08-20",
      "last_synced_at": "2026-11-19T11:51:58.677Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02109224"
    },
    {
      "nct_id": "NCT02860286",
      "title": "Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mesothelioma",
        "BAP1 Loss of Function"
      ],
      "interventions": [
        {
          "name": "Tazemetostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Epizyme, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2016-07",
      "completion_date": "2019-05",
      "has_results": true,
      "last_update_posted_date": "2021-04-09",
      "last_synced_at": "2026-11-19T11:51:58.677Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02860286"
    },
    {
      "nct_id": "NCT01865617",
      "title": "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "CD19-Positive Neoplastic Cells Present",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Acute Lymphoblastic Leukemia",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Mantle Cell Lymphoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 204,
      "start_date": "2013-05-22",
      "completion_date": "2021-03-26",
      "has_results": true,
      "last_update_posted_date": "2022-05-25",
      "last_synced_at": "2026-11-19T11:51:58.677Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01865617"
    },
    {
      "nct_id": "NCT00085813",
      "title": "Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small-Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Ispinesib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2003-12",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2010-10-04",
      "last_synced_at": "2026-11-19T11:51:58.677Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Greensboro",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00085813"
    },
    {
      "nct_id": "NCT02581982",
      "title": "Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Transitional Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2016-04-06",
      "completion_date": "2022-12-19",
      "has_results": true,
      "last_update_posted_date": "2023-01-10",
      "last_synced_at": "2026-11-19T11:51:58.677Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02581982"
    },
    {
      "nct_id": "NCT00100880",
      "title": "Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Atypical Teratoid/Rhabdoid Tumor",
        "Childhood Central Nervous System Germ Cell Tumor",
        "Childhood Choroid Plexus Tumor",
        "Childhood Craniopharyngioma",
        "Childhood Ependymoblastoma",
        "Childhood Grade I Meningioma",
        "Childhood Grade II Meningioma",
        "Childhood Grade III Meningioma",
        "Childhood High-grade Cerebellar Astrocytoma",
        "Childhood High-grade Cerebral Astrocytoma",
        "Childhood Infratentorial Ependymoma",
        "Childhood Low-grade Cerebellar Astrocytoma",
        "Childhood Low-grade Cerebral Astrocytoma",
        "Childhood Medulloepithelioma",
        "Childhood Mixed Glioma",
        "Childhood Oligodendroglioma",
        "Childhood Supratentorial Ependymoma",
        "Recurrent Childhood Brain Tumor",
        "Recurrent Childhood Cerebellar Astrocytoma",
        "Recurrent Childhood Cerebral Astrocytoma",
        "Recurrent Childhood Ependymoma",
        "Recurrent Childhood Medulloblastoma",
        "Recurrent Childhood Pineoblastoma",
        "Recurrent Childhood Subependymal Giant Cell Astrocytoma",
        "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor",
        "Recurrent Childhood Visual Pathway and Hypothalamic Glioma"
      ],
      "interventions": [
        {
          "name": "lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "perfusion-weighted magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "diffusion-weighted magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 45,
      "start_date": "2004-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-30",
      "last_synced_at": "2026-11-19T11:51:58.677Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00100880"
    },
    {
      "nct_id": "NCT05665062",
      "title": "Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "CLL/SLL",
        "NHL",
        "Mantle Cell Lymphoma",
        "Follicular Lymphoma",
        "Large B-cell Lymphoma",
        "Indolent B-Cell Non-Hodgkin Lymphoma",
        "Diffuse Large B Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "SYNCAR-001",
          "type": "DRUG"
        },
        {
          "name": "STK-009",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synthekine",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2023-04-23",
      "completion_date": "2041-11",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-11-19T11:51:58.677Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Buffalo, New York • New York, New York + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05665062"
    }
  ]
}